TEAD-IN-13

TEAD-IN-13 (64) is a potent, orally bioavailable TEAD autopalmitoylation inhibitor with an IC50 under 100 nM. Its 3.2-hour half-life in mice supports in vivo studies of Hippo pathway dysregulation in cancer research, enabling investigation of TEAD-dependent transcription in cellular and animal models.